A Phase 4 interventional study of IV Acetaminophen (Treatment A) and Oral Acetaminophen (Treatment B) in Pain, sponsored by Mallinckrodt. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-05.
Sponsored by Mallinckrodt · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 137 studies testing acetaminophen in Pain — 5 open to participants now, 5 under way, none of them phase 3. Acetaminophen · Pain.
Among the 137 studies testing acetaminophen in Pain, this one is the 80th largest by enrollment, is one of 12 that started in 2015, is one of 67 in phase 4, and was the 89th registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →5 of the 137 studies testing acetaminophen in Pain are open now, in 3 countries. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
Horizon Health Network · Sites in Canada
Ages 19+
University of Gaziantep · Sites in Turkey
Ages 18–75
Western Galilee Hospital-Nahariya · Sites in Israel
Ages 18–45 · Women only · Healthy volunteers
Baskent University · Sites in Turkey
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years to 55 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
137 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 18 · Phase 3 25 · Phase 4 67
First in 2003; this study’s year is marked. 12 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 79 is above the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 95 across the 137 interventional studies. Of the 115 that completed or were terminated, 53 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 137 have an industry lead sponsor. The 10 most frequent:
This study is registered under Mallinckrodt, one of the names counted as Keenova Therapeutics plc. Under that name alone:
Mallinckrodt is the lead sponsor of 87 studies on the registry; none are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 15 (100%) have results posted.
16 studies in Pain by Keenova Therapeutics plc: none open now, none under way, none of them phase 3. Of 16 finished, 10 (63%) have results posted.
Among the 16 studies in Pain by Keenova Therapeutics plc, this one is the 9th largest by enrollment, is the only one that started in 2015, is one of 2 in phase 4, and was the 15th registered.
Keenova Therapeutics plc’s Pain studies by the year they started, since 2001.
4 of the studies testing acetaminophen in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07512297University of GaziantepPain Control During ESWL Using Non-Opioid Analgesics | 2027-01-01 |
| NCT07368738Horizon Health NetworkIntravenous Acetaminophen and Ketorolac for Pain Management During Extracorporeal Shockwave Lithotripsy | 2027-04 |
| NCT06613178McGill University Health Centre/Research Institute of the McGill University Health CentreIntravenous Acetaminophen After Cardiac Surgery - Definitive Study | 2027-07-01 |
| NCT07536425Western Galilee Hospital-NahariyaPreoperative Indomethacin and Paracetamol for Pain Management During Oocyte Retrieval in IVF Patients | 2027-10-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 137 studies testing acetaminophen in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Keenova Therapeutics plc’s 16 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate two experimental pain models to see if they would be useful for comparing different products for reduction in pain intensity.
The models evaluated were the ultraviolet-B (UVB) burn and intradermal capsaicin experimental pain models. Medications compared were a single dose each, of intravenous (IV) acetaminophen, oral acetaminophen, placebo, and IV morphine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants receive IV acetaminophen as one of 4 interventions in random sequence
Drug: IV Acetaminophen (Treatment A) · Drug: Placebo (Treatment C)
All participants receive oral acetaminophen as one of 4 interventions in random sequence
Drug: Oral Acetaminophen (Treatment B) · Drug: Placebo (Treatment C)
All participants receive placebo as one of 4 interventions in random sequence
Drug: Placebo (Treatment C)
All participants receive morphine as one of 4 interventions in random sequence
Drug: Placebo (Treatment C) · Other: Morphine (Treatment D)
Acetaminophen administered by intravenous (IV) infusion
Also known as: OFIRMEV
Acetaminophen administered by oral tablets
Also known as: Acetaminophen tablets
Placebo administered by IV infusion or oral tablets
Also known as: IV Placebo, Placebo tablets
Morphine administered by IV infusion
Also known as: IV Morphine
Part 1: Change From Baseline in Pain Intensity at Hour 6 Using the Thermal Suprathreshold Pain in the Ultraviolet-B (UVB) Burn Pain Model
The UVB burn pain model is a validated screening tool for pain killers in clinical drug development. A temperature of 50 degrees centigrade (°C) is used to burn the participant for 5 seconds. Then the participant rates his pain on a scale from 0 (no pain) to 10 (most intense pain). That score is recorded as baseline. Then the participant rates his pain again six hours after taking the assigned medication. The average at baseline is subtracted from the average at hour 6. Because this is a measure of reduction in pain intensity, a higher score is better (it means there is more pain relief).
Time frame: within 6 hours
Part 2: Observed Thermal Suprathreshold Pain Intensity in the UVB Burn Area
Participants rated their pain intensity on a scale of 0 (no pain) to 10 (most intense pain). The observed mean and standard deviation are disclosed through Hour 6
Time frame: within 6 hours
A total of 79 participants were enrolled in the study. 12 participants in Part 1 and 66 participants in Part 2 were randomized to sequence, and received at least one dose of the study treatment.
| Milestone | Part 1 |
|---|---|
| Started | 12 |
| Safety population | 12 |
| Modified intent to treat (mitt) | 12 |
| Per protocol population | 8 |
| Completed | 11 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Milestone | Part 1 |
|---|---|
| Started | 67 |
| Treated (safety population) | 66 |
| Modified intent to treat population | 66 |
| Pharmacokinetic population | 65 |
| Per protocol population | 64 |
| Completed | 64 |
| Not completed | 3 |
| Withdrew: Adverse event | 2 |
| Withdrew: Withdrawal by subject | 1 |
The UVB burn pain model is a validated screening tool for pain killers in clinical drug development. A temperature of 50 degrees centigrade (°C) is used to burn the participant for 5 seconds. Then the participant rates his pain on a scale from 0 (no pain) to 10 (most intense pain). That score is recorded as baseline. Then the participant rates his pain again six hours after taking the assigned medication. The average at baseline is subtracted from the average at hour 6. Because this is a measure of reduction in pain intensity, a higher score is better (it means there is more pain relief).
| score on a scale | IV Acetaminophen | Oral Acetaminophen | Placebo | Morphine |
|---|---|---|---|---|
| Part 1: Change From Baseline in Pain Intensity at Hour 6 Using the Thermal Suprathreshold Pain in the Ultraviolet-B (UVB) Burn Pain Model | 0.73 ± 1.104 | -0.64 ± 1.804 | -0.36 ± 1.567 | 0.36 ± 1.206 |
Participants rated their pain intensity on a scale of 0 (no pain) to 10 (most intense pain). The observed mean and standard deviation are disclosed through Hour 6
| scores on a scale | Part 2: IV Acetaminophen | Part 2: Oral Acetaminophen | Part 2: Placebo | Part 2: IV Morphine |
|---|---|---|---|---|
| Baseline | 5.4 ± 1.30 | 5.5 ± 1.40 | 5.5 ± 1.32 | 5.6 ± 1.40 |
| 0.25 Hours | 5.2 ± 1.39 | 5.3 ± 1.48 | 5.5 ± 1.28 | 4.9 ± 1.56 |
| 0.5 Hours | 5.0 ± 1.34 | 5.1 ± 1.36 | 5.3 ± 1.28 | 4.7 ± 1.50 |
| 0.75 Hours | 5.0 ± 1.37 | 5.1 ± 1.30 | 5.4 ± 1.26 | 4.7 ± 1.62 |
| 1 Hour | 5.0 ± 1.44 | 4.9 ± 1.23 | 5.2 ± 1.34 | 4.6 ± 1.55 |
| 2 Hours | 5.3 ± 1.13 | 5.1 ± 1.26 | 5.6 ± 1.28 | 5.1 ± 1.50 |
| 3 Hours | 5.4 ± 1.30 | 5.2 ± 1.44 | 5.5 ± 1.23 | 5.0 ± 1.67 |
| 4 Hours | 5.5 ± 1.17 | 5.4 ± 1.40 | 5.5 ± 1.30 | 5.2 ± 1.42 |
| 6 Hours | 5.6 ± 1.32 | 5.5 ± 1.30 | 5.5 ± 1.34 | 5.4 ± 1.45 |
Collected over From first dose up to Day 46. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: IV Acetaminophen | 0/12 (0%) | 0/12 (0%) | 2/12 (16.7%) |
| Part 1: Oral Acetaminophen | 0/12 (0%) | 0/12 (0%) | 2/12 (16.7%) |
| Part 1: Placebo | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| Part 1: Morphine | 0/12 (0%) | 0/12 (0%) | 8/12 (66.7%) |
| Part 2: IV Acetaminophen | 0/64 (0%) | 0/64 (0%) | 10/64 (15.6%) |
| Part 2: Oral Acetaminophen | 0/65 (0%) | 0/65 (0%) | 12/65 (18.5%) |
| Part 2: Placebo | 0/65 (0%) | 0/65 (0%) | 14/65 (21.5%) |
| Part 2: Morphine | 0/64 (0%) | 0/64 (0%) | 38/66 (57.6%) |
| Event | Part 1: IV Acetaminophen | Part 1: Oral Acetaminophen | Part 1: Placebo | Part 1: Morphine | Part 2: IV Acetaminophen | Part 2: Oral Acetaminophen | Part 2: Placebo | Part 2: Morphine |
|---|---|---|---|---|---|---|---|---|
| DizzinessNervous system disorders | 1/12 | 0/12 | 0/12 | 4/12 | 1/64 | 2/65 | 1/65 | 20/66 |
| SomnolenceNervous system disorders | 0/12 | 0/12 | 0/12 | 4/12 | 0/64 | 0/65 | 1/65 | 10/66 |
| SyncopeNervous system disorders | 0/12 | 0/12 | 0/12 | 3/12 | 0/64 | 0/65 | 0/65 | 1/66 |
| NauseaGastrointestinal disorders | 0/12 | 0/12 | 0/12 | 1/12 | 0/64 | 1/65 | 1/65 | 9/66 |
| VomitingGastrointestinal disorders | 0/12 | 0/12 | 0/12 | 1/12 | 0/64 | 0/65 | 1/65 | 5/66 |
| HeadacheNervous system disorders | 1/12 | 0/12 | 0/12 | 0/12 | 1/64 | 4/65 | 3/65 | 4/66 |
| ParaesthesiaNervous system disorders | 0/12 | 0/12 | 0/12 | 1/12 | 1/64 | 1/65 | 2/65 | 5/66 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/12 | 1/12 | 1/12 | 0/12 | 0/64 | 0/65 | 0/65 | 0/66 |
| Axillary PainGeneral disorders | 0/12 | 0/12 | 1/12 | 0/12 | 0/64 | 0/65 | 0/65 | 0/66 |
| Injection Site ReactionGeneral disorders | 0/12 | 0/12 | 1/12 | 0/12 | 0/64 | 0/65 | 0/65 | 0/66 |
Safety Population, defined as participants enrolled in the study that received any quantity of study drugs. All new participants were enrolled in Part 2.
| Age, Continuous(years) | Part 1 | Part 2 | Total |
|---|---|---|---|
| Mean | 28.9 (19 to 49) | 26.5 (18 to 52) | 26.9 (18.2 to 51.5) |
| Sex: Female, Male(Participants) | Part 1 | Part 2 | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 12 | 66 | 78 |
| Race/Ethnicity, Customized(Participants) | Part 1 | Part 2 | Total |
|---|---|---|---|
| Race, White — Not Hispanic or Latino | 12 | 60 | 72 |
| Race, White — Hispanic or Latino | 0 | 6 | 6 |
| Region of Enrollment(Participants) | Part 1 | Part 2 | Total |
|---|---|---|---|
| United States | 12 | 66 | 78 |
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2015 to primary completion in Jun 2016, 6 months.
Results were first posted in Dec 2019, 3 years 6 months after primary completion.
Of 295 phase 4 interventional studies under Pain, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's 6 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acetaminophen